Parkinson's Disease (PD) is the second most common neurodegener-ative disorder. It currently affects 4.1 to 4.6 million people over 50 years worldwide, and t his figure is expected to rise to 8. 7 to 9.3 mil-lion in 25 years because of the increasing life expectancy. People with PD are affected by motor as well as cognitive and behavioural prob-lems and the available treatments mostly deal wit h symptom control. This work addresses the importance of emotion-cognition interactions in PD by looking at the effect of emotions on working memory for faces and t he influence of treatment. I compared face working mem-ory in younger and older healt hy people and found a selective deficit for happy, angry and fearful faces in the older group. Patients with PD were overall impaired compared to age-matched healthy controls but showed a relative strength in memory for sad faces that reverted to a benefit for angry faces after treatment with drugs acting on the neurotransmitter dopamine. This t hesis also assesses the effects of a non-pharmacological intervention, neurofeedback based on functional magnetic resonance imaging ( fMRI), on motor functions. T his inter-vention study suggests that it is possible to alter brain activation wit h the use of fMRI neurofeedback and improve motor functioning in ev-eryday life. These studies converge to suggest that both pharmacolog-ical ( dopaminergic drugs) and non-pharmacological (neurofeedback) interventions have effects on cognition and motor functions in PD .